Semaglutida vs Retatrutida
Semaglutida is mainly studied for appetite control, metabolic regulation. while Retatrutida is studied for metabolic regulation, definition. The difference is in the mechanism and the evidence, not in which is "better": it depends on the goal.
| Semaglutida | Retatrutida | |
|---|---|---|
| Category | Metabolic | Metabolic |
| Studied for | Appetite control, metabolic regulation. | Metabolic regulation, definition. |
| How it acts | A molecule associated with the GLP-1 pathway, studied for its relationship with appetite control, satiety and glucose regulation. | An investigational molecule associated with multiple incretin pathways, studied for its relationship with metabolic regulation and body composition. |
| Evidence level | Human trials available | Human trials available |
How they differ
Although sometimes mentioned together, Semaglutida and Retatrutida do not target the same thing. Semaglutida: A molecule associated with the GLP-1 pathway, studied for its relationship with appetite control, satiety and glucose regulation. Retatrutida: An investigational molecule associated with multiple incretin pathways, studied for its relationship with metabolic regulation and body composition.
See full entry: Semaglutida → · See full entry: Retatrutida →
Want to truly understand it, not memorize it?
The course explains each peptide at a university level: how it acts, what outcomes are studied, what it combines with and when to pause. No doses: the protocol is defined by a professional.
See the course → Start with the free test →Frequently asked questions
What is the main difference between Semaglutida and Retatrutida?
Semaglutida targets appetite control, metabolic regulation. and Retatrutida targets metabolic regulation, definition. They act through different pathways, so the choice depends on your goal, not on which is "stronger".
Can they be studied together?
Combinations are studied by goal in the literature, but combining is not just adding: it changes the safety profile. What to combine and how is decided with a professional; here we only explain what each is studied for.
Which has more human evidence?
Based on the references we verified, Semaglutida has more human studies of this pair. Each one's evidence level is in the table above, and the references with their PMID are at the end.
Other comparisons
Was this page useful?
Research moves, and when something relevant changes we update the page. If you want to hear about it for Semaglutida vs Retatrutida or any other compound, leave your email. The introductory guide comes with it. No spam, no list-selling; one click to unsubscribe.
References
Every entry links to its record on PubMed, the US National Library of Medicine database. Open them and check. We would rather have a reader who verifies than one who takes our word for it.
Some title in this list contains a figure, because that is how the study was published and we reproduce titles verbatim: trimming them would make the citation impossible to verify. A title is not a protocol. What amount suits a particular person is decided by a professional who knows their case, never by the headline of a trial.
- Once-Weekly Semaglutide in Adults with Overweight or Obesityhuman N Engl J Med · 2021 · PMID 33567185 →
- Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trialhuman Lancet · 2021 · PMID 33667417 →
- Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trialhuman JAMA · 2021 · PMID 33755728 →
- Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trialhuman Nat Med · 2022 · PMID 36216945 →
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trialhuman N Engl J Med · 2023 · PMID 37366315 →
- Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USAhuman Lancet · 2023 · PMID 37385280 →
- Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trialhuman Nat Med · 2024 · PMID 38858523 →
- Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trialhuman Lancet Diabetes Endocrinol · 2025 · PMID 40609566 →
Educational content. It does not include doses, protocols or preparation: that is defined by a professional.